Get notified when BBOT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (new) — The company disclosed a material weakness in internal controls over financial reporting, which could lead to material misstatements.
- Insider Economic Interests Diverge (new) — The sponsor and insiders will realize gains on founder shares even if the stock trades below the IPO price, while public shareholders only profit above $10.00.
BridgeBio Oncology Therapeutics (BBOT) to go public via SPAC merger with Helix Acquisition Corp. II, offering up to 28M shares
Filed July 10, 2025 · ~1 min read
Key Changes
-
high
BBOT is a pre-revenue biotech with no approved products and a GAAP net loss of $0.5M; it has never completed a clinical trial.
Risk Factors verify on EDGAR → -
high
The offering is a SPAC business combination with Helix Acquisition Corp. II, offering up to 28,000,000 shares of common stock.
The Offering verify on EDGAR → -
high
Net proceeds to the company are $184M, which together with existing cash is expected to fund operations into 2027.
Risk Factors verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CBRL 10-K) is open in full — no account needed.
Partner
Trade BBOT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify